// App-Quantinova.ai

: P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs).

Researchers

Presenter

  • Danka Zebic

Principal Investigators

  • Martin R. Stockler

  • Andrew James Martin

  • Farzana D. Pashankar

  • Ben Tran

  • Danish Mazhar

  • Robert A Huddart

  • Matthew Wheater

  • Euan Thomas Walpole

  • Elaine Dunwoodie

  • Darren R. Feldman

  • Alison Jane Birtle

  • Amanda Gwendolyn Stevanovic

  • David Wyld

  • Fritha J. Hanning

  • Peter S. Grimison

Medical Centers

  • Auckland City Hospital, Auckland, New Zealand

  • NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Nepean Cancer Care Centre, Kingswood, Australia

  • Royal Brisbane and Women's Hospital, Herston, Australia

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Princess Alexandra Hospital, Brisbane, Australia

  • Yale Cancer Center, Yale School of Medicine, New Haven, CT

  • University of Southampton, Southampten, United Kingdom

  • Royal Marsden Hospital, Surrey, United Kingdom

  • St. James's University Hospital, Leeds, United Kingdom

  • Rosemere Cancer Centre, Lancs Teaching Hospitals, & University of Manchester, University of Central Lancashire, Preston, United Kingdom

  • Chris O'Brien Lifehouse, Sydney, Australia

Locations

  • United Kingdom

  • New Zealand

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Granulocyte colony-stimulating factor

Drug/Treatment

  • PEGylated G-CSF

  • Filgrastim

  • Etoposide

  • Etoposide phosphate

  • Cisplatin

  • Bleomycin

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multinational

Phase

  • III

Study Id's

  • NCT02582697

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved